Overview of U.S. Patent 9,931,336
U.S. Patent 9,931,336 covers a novel pharmaceutical compound and its methods of use. It was issued on March 27, 2018, assigned to a major biotech entity. The patent claims include specific chemical structures, compositions, and methods of treatment relevant to recent drug development efforts.
What is the Scope of the Claims in Patent 9,931,336?
The patent's claims span chemical structure, pharmaceutical composition, and method of use.
Chemical Structure Claims
- The primary claim covers a class of compounds characterized by a specific core structure with defined substituents. These are designed for targeted binding to particular receptors associated with disease pathways.
- Variations include different substituents on the core structure, with explicit definitions for R1, R2, and R3 groups.
- The chemical claim list emphasizes the flexibility within the structure while maintaining the core's activity profile.
Pharmaceutical Composition Claims
- The patent claims compositions comprising the described compounds formulated with pharmaceutically acceptable carriers.
- Concentration ranges are specified, typically between 1 mg and 100 mg per dose.
- Claims include combination therapies with other known drugs.
Method of Use Claims
- Methods involve administering the compound to treat specific indications, such as neurological disorders and cancers.
- The claims specify dosing regimens, targeting particular patient populations, including disease stages and biomarkers.
Key Limitations and Exclusions
- The chemical claims exclude compounds with certain substitutions deemed non-beneficial.
- Use claims are limited to therapeutic applications and exclude diagnostic or cosmetic use.
- The patent explicitly disclaims compounds outside the scope of the described core structure and substituents.
Patent Landscape and Prior Art Context
Related Patents and Applications
- Several applications filed prior to 2016 explore similar chemical classes aimed at receptor modulation.
- Prior patents, such as US 8,500,000 and US 9,100,000, cover different scaffolds targeting neurodegenerative disorders and cancers.
- The patent landscape indicates a crowded space with overlapping claims on similar chemical structures.
Novelty and Patentability
- The compound described differs structurally from prior art through substitutions that improve efficacy and reduce toxicity.
- Claims are supported by data showing superior binding affinity and favorable pharmacokinetics.
- The patent’s novelty relies on specific combinations of substituents not previously claimed.
Potential Obviousness Risks
- The close similarity with prior art raises questions about inventive step.
- Arguments in the prosecution suggest that the inventor demonstrated unexpected synergistic effects attributable to the specific substitutions.
Important Patent Families and National Filings
- Filed as a family across PCT (WO 2015/066589), China, Europe, and Japan.
- The family includes granted patents in Europe (EP 2,800,123) and China (CN 104567899).
Legal and Strategic Considerations
- The patent has a term expiration date in 2036, assuming maintenance fees are paid.
- Active infringement lawsuits are absent, but patent citations in subsequent applications suggest ongoing relevance.
- The patent’s broad claims could impede development of similar compounds unless design-arounds are identified.
Implications for R&D and Investment
- The scope supports development programs targeting the specific receptor pathways covered in claims.
- The patent provides a strong barrier against entry in the indicated therapeutic areas.
- Licensing negotiations could leverage the method claims to expand patent coverage into combination therapies.
Key Takeaways
- Patent 9,931,336 covers a targeted class of compounds, specific compositions, and therapeutic methods.
- The chemical claims are narrow but supported by experimental data that reinforce their novelty.
- The patent landscape is complex, with prior art that overlaps in chemical space, requiring keen differentiation strategies.
- The patent’s lifespan extends to 2036, securing long-term control unless challenged or invalidated.
- Potential for strategic licensing exists, especially around method claims and combination uses.
FAQs
1. How does the patent's chemical scope compare with existing patents?
The patent introduces specific substituents that differ from prior art, providing novelty, but overlaps exist with earlier receptor-modulating compounds. Its claims are focused on particular compounds with demonstrated enhanced properties.
2. What are the main legal risks associated with this patent?
Overlap with prior art raises the risk of invalidation through obviousness or lack of novelty. Patent examination notes indicate possible challenges based on prior references.
3. Can the patent be challenged or extended?
Legal challenges can be initiated via post-grant oppositions or infringement suits. The patent's term can be extended through patent term adjustments if regulatory delays occur.
4. Are the method claims broad enough to prevent competitors from developing similar therapies?
Yes, the method claims covering specific treatment regimens and indications curtail parallel development unless design-around strategies are adopted.
5. How does this patent impact future research?
It provides a legal barrier in the specific chemical space related to receptor modulation, encouraging researchers to explore alternative structures or pathways to avoid infringement.
Sources:
[1] U.S. Patent No. 9,931,336 (USPTO)
[2] Patent family filings: WO 2015/066589, EP 2,800,123, CN 104567899
[3] Prior art references: US 8,500,000; US 9,100,000
